Laboratorios Rovi : Q2 2021 beat our higher-than-consensus expectations but lower expectations for the gross margin in H2 prompt us to cut our rating to Neutral
>Laboratorios Rovi released a good set of results in Q2 2021 - Total revenues increased +77% y-o-y to € 160m (33% above our estimates) boosted by strong demand of Becat (+69% y-o-y) and significantly helped by the Moderna agreement on the mRNA COVID-19 vaccine (sales of toll manufacturing +167% y-o-y, 62% above expectations). Despite the lower gross margin, EBITDA was 7% ahead our expectations and beat consensus by 19%. Strong cash flow generation - G...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.